Citius Pharmaceuticals to Present Mino-Lok® and COVID-related Respiratory Treatment Update at Benzinga Global Small Cap Conference on Thursday, May 13

Rhea-AI Summary

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced participation in the Benzinga Global Small Cap Conference on May 13-14, 2021. CEO Myron Holubiak will present on May 13 at 1:50 p.m. ET, focusing on the company's pipeline strategy, particularly a novel stem-cell program for treating Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. This condition currently lacks FDA-approved therapeutic options. Additionally, Citius's Mino-Lok® is undergoing a Phase 3 trial for catheter-related bloodstream infections.

Positive

• Participation in Benzinga Global Small Cap Conference to highlight business.
• Presentation by CEO focusing on innovative treatment for ARDS, a critical market area.
• Mino-Lok® undergoing Phase 3 superiority trial, indicating advancement in product development.

Negative

• None.

CRANFORD, N.J., May 4, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it will participate in the virtual Benzinga Global Small Cap Conference being held May 13-14, 2021.

Citius President and Chief Executive Officer Myron Holubiak will present at 1:50 p.m. ET on Thursday, May 13. Investors may register for the conference at the event website, and Mr. Holubiak's presentation may be viewed live on the Benzinga YouTube channel.

During his presentation, Mr. Holubiak will focus on the Company's pipeline strategy and highlight Citius's novel stem-cell program for the treatment of Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition, and the most common cause of respiratory failure and death in COVID-19 patients. Currently, there is no FDA-approved drug therapy available for ARDS.

About Citius Pharmaceuticals, Inc.
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The Company's lead product candidate, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), is currently enrolling patients in a Phase 3 pivotal superiority trial.  Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.  For more information, please visit www.citiuspharma.com.

Investor Relations for Citius Pharmaceuticals:
Andrew Scott
Vice President, Special Projects
T: 908-967-6677 x105
E: ascott@citiuspharma.com

Ilanit Allen
T: 908-967-6677 x113
E: iallen@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-mino-lok-and-covid-related-respiratory-treatment-update-at-benzinga-global-small-cap-conference-on-thursday-may-13-301283314.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

What will Citius Pharmaceuticals present at the Benzinga Global Small Cap Conference?

Citius Pharmaceuticals will present on its pipeline strategy and its novel stem-cell program for treating Acute Respiratory Distress Syndrome (ARDS) on May 13, 2021.

When is Citius Pharmaceuticals' presentation at the Benzinga conference?

Citius Pharmaceuticals' CEO will present on May 13, 2021, at 1:50 p.m. ET.

What clinical trial is Citius Pharmaceuticals currently conducting?

Citius Pharmaceuticals is currently enrolling patients in a Phase 3 pivotal superiority trial for its lead product candidate, Mino-Lok®.

What is the focus of Citius Pharmaceuticals' stem cell program?

Citius Pharmaceuticals' stem cell program focuses on developing a treatment for Acute Respiratory Distress Syndrome (ARDS), particularly in the context of COVID-19.

What is the significance of the Mino-Lok® product for Citius Pharmaceuticals?

Mino-Lok® is significant for Citius Pharmaceuticals as it is an antibiotic lock solution currently in a pivotal Phase 3 trial for catheter-related bloodstream infections.